Impact of an oral gonadotropin‐releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained‐release gonadotropin‐releasing hormone agonist: A case report

Postoperative hormone therapy for hormone‐sensitive patients with breast cancer is important to prevent a recurrence. As hormone therapy does not induce infertility in patients, fertility‐preserving therapy is not provided during treatment. Here, however, we performed controlled ovarian stimulation...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2021-12, Vol.47 (12), p.4472-4477
Main Authors: Hanada, Tetsuro, Kimura, Fuminori, Kitazawa, Jun, Morimune, Aina, Murakami, Takashi
Format: Article
Language:English
Subjects:
Agonists
Breast cancer
Breast Neoplasms - drug therapy
Cancer therapies
Case reports
Chemotherapy
Delayed-Action Preparations
Endocrine therapy
Female
Fertility
Fertilization in Vitro
Freezing
Gonadotropin-Releasing Hormone
Gonadotropins
gonadotropin‐releasing hormone agonist
gonadotropin‐releasing hormone antagonist
Humans
Infertility
oncofertility
Ovarian hyperstimulation syndrome
Ovarian Hyperstimulation Syndrome - chemically induced
Ovaries
Ovulation Induction
Patients
Pituitary (anterior)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Postoperative hormone therapy for hormone‐sensitive patients with breast cancer is important to prevent a recurrence. As hormone therapy does not induce infertility in patients, fertility‐preserving therapy is not provided during treatment. Here, however, we performed controlled ovarian stimulation and embryo freezing for fertility preservation under the influence of a sustained‐release gonadotropin‐releasing hormone agonist in a patient with breast cancer whose postoperative treatment plan was changed from hormone therapy to chemotherapy. After oocyte retrieval, the patient developed treatment‐resistant severe symptomatic ovarian hyperstimulation syndrome. Following treatment with oral gonadotropin‐releasing hormone antagonist, her symptoms immediately improved, and she could receive chemotherapy on schedule.
ISSN:1341-8076
1447-0756
DOI:10.1111/jog.15059